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Abstract: Over the last 10 years, it has become clear that patients with head and neck 
cancer can be stratified into two distinct subgroups on the basis of the etiology of their 
disease. Patients with human papillomavirus-related cancers have significantly better 
survival rates and may necessitate different therapeutic approaches than those with tobacco 
and/or alcohol related cancers. This review discusses the various biomarkers currently in 
use for identification of patients with HPV-positive cancers with a focus on the advantages 
and limitations of molecular and nano-scale markers.  
Keywords:  human papillomavirus; head and neck cancer; in situ hybridization; next 
generation sequencing; biomarkers 
 
1. Introduction 
Squamous cell carcinoma of the head and neck is the sixth most common cancer worldwide, with 
nearly 50,000 cases diagnosed annually [1]. Patients are often diagnosed with locally advanced (i.e., 
stage IV) disease with a significant burden of lymph node involvement. Optimal treatment for these 
patients usually involves evaluation in a multidisciplinary setting with the coordination of surgery, 
chemotherapy, and radiation therapy. In many cases combinations of therapy are used (reviewed in [2]).  
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Over the last 10 years, a growing proportion of patients with head and neck cancer have been found 
to have tumors attributable to the human papillomavirus (HPV). This virus has long been known to 
cause cancers of the uterine cervix in women and of the anal canal in both men and women. Initially 
described in head and neck cancer by Syrjanen and colleagues due to histologic similarities between 
oropharyngeal cancers and cervical cancers [3], HPV is now thought to cause 30–65% of head and 
neck cancers [4,5].  
2. Importance of Human Papillomavirus in Head and Neck Cancer 
There are currently more than 100 HPV subtypes that can be classified into low-risk and high-risk 
on the basis of their association with invasive malignancies. Just over a dozen HPV types have been 
classified as high risk. Of these, head and neck cancer is almost exclusively caused by HPV-16 which 
accounts for >90% of cases [6,7]. This is in stark contrast to cervical cancer where HPV-16 and   
HPV-18 together account for only approximately 70% of cases [8,9]. To date, it is not known why 
head and neck cancers arise almost exclusively as a result of HPV-16 infection although it has been 
postulated to be due to localization of a factor (not yet identified) necessary for HPV internalization on 
the epithelial surface of the head and neck.  
In addition, HPV does not appear to affect all mucosal head and neck sites equally [6]. The vast 
majority of HPV-positive head and neck cancers arise from the mucosa lining the oropharynx (i.e., 
tonsil, base of tongue, and soft palate) where the rate of HPV positivity has been as high as 80% in 
some studies [6,10,11]. Given the proximity of head and neck subsites (e.g., tonsil vs. retromolar 
trigone) and the difficulty in assigning a site of origin in some large primary tumors, it is also possible 
that HPV-positive cancers arising in other head and neck subsites are actually misclassified and truly 
arise from either the base of tongue or the tonsil. 
There appears to be significant geographic and temporal variation in the rates of HPV-positive head 
and neck cancers with higher rates in the US compared to Europe (47% vs. 28%, respectively) [12] and 
several studies showing an increasing incidence over the last 20 years [13,14]. Whereas the rates of 
HPV-negative HNSCC and incidence of oral cavity tumors have seen a slight decrease over the same 
period of time [7,15].  
HPVs are DNA viruses that are encoded by approximately 8000 base pair genomes. The double 
stranded circular DNA encodes eight proteins: E1, E2, E4, E5, E6, E7, L1, and L2. Carcinogenesis is 
thought to be driven by expression of E5, E6 and E7 with the other early genes playing important roles 
in viral gene transcription and viral DNA replication. L1 and L2 encode the capsid proteins which form 
the “coat” of the virus and which are targeted by HPV-vaccines (a topic beyond the scope of this review).  
Interestingly, while patients with HPV-associated head and neck cancers commonly present with 
more advanced disease, they have significantly improved outcomes compared with stage and comorbidity 
matched HPV-negative patients. Differences in five year overall survival between HPV-positive and 
HPV-negative patients exceed 30% in a number of retrospective analyses [10,16–19]. This difference 
is one of the largest yet identified for cancers that arise within the same tissues, have very similar 
patterns of spread, and have overlapping histology. Interestingly, even within patients with HPV-positive 
HNSCC, those with a history of significant tobacco/alcohol use show significantly worse outcomes 
than never smokers; but an outcome that remains better than those with HPV-negative disease [5].  Sensors 2012, 12  5161 
 
 
These large differences in outcome have arisen in an era during which patients with HPV-positive 
cancers were treated no differently from those with HPV-negative cancers. However, in the past 
several years the oncology community has begun to think about HPV-positive head and neck cancer as 
a different disease than traditional tobacco/alcohol related head and neck cancer [20–22]. It is hoped 
that HPV-status may ultimately aid in selecting treatment options. However, due in part to difficulties 
in determining whether a given patient’s tumor is HPV-positive or HPV-negative, clinical trials 
specific for HPV-positive patients have only recently begun enrolling patients (e.g., NCT01302834, 
NCT01530997, NCT01525927, NCT01221753, NCT01084083). In this article we will review the 
current state-of-the-art regarding biomarkers to identify patients with HPV-positive cancers with   
a focus on the advantages and limitations of molecular and nano-scale markers.  
3. Non-Amplified Detection  
3.1. Southern Blot: The Gold Standard 
Originally described by Edwin Southern in 1975, the “Southern Blot” is the gold standard test to 
measure the number of copies of a given gene or to analyze stretches of DNA that are too repetitive for 
PCR amplification or classical sequencing methods [23,24]. While techniques very considerably, 
Southern blots are labor intensive pursuits that require isolation of relatively large amounts of genomic 
DNA, digestion with restriction endonucleases, separation of DNA by electrophoresis, transfer of 
DNA to a nitrocellulose membrane, synthesis of radio-labeled nucleic acid probe(s), hybridization, and 
finally, exposure of film (Figure 1).  
Figure 1. A type specific viral genome is digested with chosen restriction enzymes and 
resulting oligonucleotide fragments are radioactively labeled. Simultaneously, tumor DNA 
is also subjected to restriction digestion. Tumor DNA fragments are separated by agarose 
electrophoresis and transferred to a nitrocellulose membrane. Radioactively labeled probes 
are allowed to hybridize with cellular DNA, washed, and detected via overnight exposure 
of film to the membrane. Bands of HPV DNA present within the original tumor DNA can 
be detected due to hybridization with labeled probes. 
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At this time, these steps are not easily amenable to automation. In addition, and of concern to  
a clinical lab, they typically involve multiple wash steps that produce large volumes of dilute 
radioactive waste. While Southern blots are labor intensive, they have an important role in studying 
tumor viruses such as HPV as they allow one to detect integration of the viral genome into the host 
genome. Additionally, assays can be developed with wash parameters and probes that are well suited 
to screening for multiple HPV subtypes. Southern blots can also be used to confirm the presence of 
specific HPV subtypes [25]. When compared to PCR based methods, Southern blot techniques have 
much lower false positive rates due to the detection of both a DNA fragment and the specific size of  
a digested DNA fragment. Similar to PCR based methods; Southern blots can be optimized to   
detect <0.1 copy of a given DNA sequence per cell giving them high sensitivity. However, in contrast 
to PCR based strategies, which inherently amplify the starting material, each step in a Southern blot 
results in loss of a proportion of the starting DNA. Thus the quantity of DNA needed for a Southern 
blot is orders of magnitude higher than that required for PCR based strategies.  
3.2. In Situ Hybridization 
In situ hybridization (ISH) is a commonly used in the diagnostic lab setting to test for HPV [6]. 
Using HPV type specific probes, ISH can detect either a single HPV subtype or a panel of high or low 
risk genomes [26]. HPV DNA within formalin-fixed and paraffin-embedded sections is targeted by 
using biotinylated HPV-specific probes [6]. This enables each probe to be detected using either 
colorimetric or fluorescent labels (i.e., fluorescent ISH or FISH) that can be visualized using a standard 
pathology microscope (Figure 2). Signals originating within the nuclei of cells are usually associated 
with HPV genome integration, although this is not strictly true [6]. 
Figure 2. Tumor blocks are unmasked and allowed to hybridize with HPV type specific 
probes prior to fixation and detection via either fluorescent or bright field microscopy. 
HPV DNA sequences within the nucleus of cells can be identified. 
 
Compared to Southern blot hybridization, ISH has lower specificity for HPV detection [27] and 
lower sensitivity than amplification based methods. Important advantages of ISH include the ability to 
perform assays on formalin-fixed paraffin-embedded sections without significant additional processing, 
and the ability to visualize results on a standard microscope. In addition, one can determine whether 
the hybridization occurs in tumor tissue or in normal epithelial tissues.  
3.3. Amplified Detection 
3.3.1. Polymerase Chain Reaction  
Polymerase chain reaction (PCR) allows for amplification of DNA isolated from tumor cells. 
Briefly, a DNA polymerase recognizes an oligonucleotide primer bound to a specific DNA sequence Sensors 2012, 12  5163 
 
 
(Figure 3). By using two primers that flank a targeted region of interest, after several round of 
amplification, the target has been amplified sufficiently to allow for visualization on an agarose gel. 
Either degenerate primers which amplify DNA sequences from multiple subtypes of HPV, or specific 
primers which amplify DNA sequences from a single subtype of HPV can be used so that PCR can be 
used both as a screening test for any HPV infection and to confirm the subtype of HPV identified. 
Figure 3. (A) Polymerase chain reaction (PCR) or reverse transcriptase PCR utilize either 
tumor DNA or cDNA that is reverse transcribed from tumor RNA. Oligonucleotide probes 
specific for a region of DNA are then used to amplify a given sequence region. The use of 
a labeled probe (star) allows for real-time detection of amplification products (B). 
 
The resulting PCR products from one or more HPV subtype can be detected by oligonucleotide 
array. Briefly, type-specific probes are plated onto an array. The PCR product is hybridized to the chip 
and resulting signals are visualized with a DNA chip scanner. This type of assay can have a sensitivity 
approached 95% and has the added benefit of being able to detect multiple HPV types within a single 
specimen [28,29]. This type of assay can also be used to detect amplified mRNA sequences (discussed 
more below) that may correlate with progression to invasive disease [30]. Sensors 2012, 12  5164 
 
 
Unlike standard PCR that amplifies genomic DNA, reverse transcriptase PCR (RT-PCR) utilizes 
RNA that is first reverse transcribed into cDNA. Following the generation of cDNA, PCR is performed 
as described above.  
Quantitation of products for both standard PCR and RT-PCR can be performed by agarose   
gel electrophoresis. Alternatively, products can be detected in real-time with the use of DNA 
sequence-specific probes or fluorescent dyes (Figure 3). qRT-PCR allows for relative quantitation of 
RNA levels if appropriate controls are performed and can be used to determine whether an HPV 
infection is transcriptionally active (i.e., does the viral DNA present result in production of mRNA and 
viral proteins). Due to the high dynamic range of qRT-PCR (>7 logs of input), one can detect RNA 
sequences present at very low concentrations that may not be identified by conventional PCR [31].  
Both PCR and RT-PCR are highly sensitive tests owing to the exponential amplification of target 
sequences that lie between two priming sequences. In theory these techniques can detect a single copy 
of a target sequence within a given sample. In reality, this high sensitivity can lead to false positive 
results either through the inclusion of random HPV genomes (particularly troublesome in labs which 
commonly study HPV) or by detection of HPV genomes within the investigated tissues, but that are 
not causative for the malignancy. Probe based qRT-PCR, which utilizes a third probe that lies within 
the amplified region can significantly decrease the risk of false positives.  
These tests can also be used to estimate the integration status of the HPV genome. Upon integration 
of the viral genome, both the L1 and E2 genes are typically disrupted and lost. Samples that retain E6 
and E7 expression, but do not express L1 or E2 are considered to harbor integrated HPV [32,33] while 
those that express all 4 viral genes harbor episomal HPV. qRT-PCR methods can be automated at each 
step from purification of cellular RNA to production of cDNA to amplification, detection, and analysis 
so that little user effort is required. However, for both tests, the possibility of target degradation when 
fresh frozen tissue is unavailable represents a significant limitation in most clinical settings. 
3.3.2. Next-Generation Sequencing 
Next-generation sequencing (NGS) is a promising method for assessment of HPV-status on a nano 
scale. NGS utilizes high-throughput sequencing technology to simultaneously sequence many 
thousands of DNA or expressed RNA fragments (Figure 4). A number of different technologies are 
available (reviewed in [34] and [35]), but all determine the nucleotide sequences of DNA fragments 
simultaneously using ever-faster and more cost effective techniques. Over the last ten years, significant 
advances in NGS have been made so that it is now feasible to perform whole genome sequencing of an 
individual patient’s tumor in a matter of hours.  
Several groups have recently published proof-of-concept studies using two of the available   
next-generation technologies to assess for HPV status in cytology samples [36] and formalin fixed 
paraffin embedded samples [37]. NGS requires little input DNA making it an assay with extremely 
high sensitivity. In addition, to its ability to rapidly examine tumor samples for HPV DNA, NGS is 
able to determine both viral genome copy number and viral genome subtype. Finally, unlike other 
methods described above, NGS may identify co-infections with multiple HPV subtypes or associations 
with alternative viral etiologies.  Sensors 2012, 12  5165 
 
 
Figure 4. Next generation sequencing utilizes high-throughput methods to simultaneously 
determine the oligonucleotide sequence of hundreds or thousands of DNA fragments 
generated following restriction digestion of tumor DNA or reverse transcription of tumor 
RNA. Newer methods are also able to sequence RNA directly. Each commercial platform 
utilizes a different specific technology (black box) to determine the nucleotide sequence. 
 
3.4. Detection of Surrogate Markers 
3.4.1. HPV 16 Seropositivity 
While not testing whether a given patient’s tumor is related to HPV infection, exposure to HPV can 
be determined through serology. Using serum antibody detection systems, monoclonal antibodies 
raised against HPV type-specific epitopes are used to compete with a patient’s antibodies produced in 
response to HPV infection or HPV immunization. Due to high background rates in the general 
population, HPV serology is not currently useful as a screening tool [38] and at the current time plays 
no role in managing patients with head and neck cancer [39]. 
3.4.2. p16 Immunohistochemistry 
Cyclin-dependent kinase inhibitor 2A (a.k.a., p16
Ink4A or p16) is a protein involved in cell cycle 
regulation. Expression of p16 has been shown to correlate with significantly improved outcomes in 
patients with head and neck squamous cell carcinomas [11,40]. This strong correlation has led to the 
suggestion that p16 expression be incorporated into staging guidelines for head and neck cancer [20]. 
Overexpression of p16 in HPV-positive cancers results from inactivation of Rb by the HPV   
protein E7 [41]. However, we and others have shown that not all p16 positive cancers are due to HPV 
infection [40,42].  
Currently, whether patients with p16 positive, but HPV-negative cancers derive the same benefit 
from a given treatment as those with p16 positive, HPV-positive cancers remains unknown. In many 
centers, p16 testing is currently used as a surrogate for HPV status without actually detecting HPV 
DNA. To overcome this limitation, it has been proposed to couple p16 IHC with a secondary assay to 
directly detect HPV DNA or RNA [43].  
In comparison to southern blot hybridization, in situ hybridization, PCR, or RT-PCR, the detection 
of p16 by IHC requires no specialized equipment or tissue handling. Nearly all pathology laboratories 
are well equipped for IHC and proprietary kits are commercially available for p16 staining in   
formalin-fixed, paraffin-embedded tissue [44]. Shi and colleagues recently performed both qRT-PCR 
and ISH for HPV-16 and found both to be associated with improved disease free survival in   
a Canadian cohort of patients with oropharyngeal squamous cell carcinoma [45]. In their study, Sensors 2012, 12  5166 
 
 
concordance between HPV16 ISH and HPV-16 E6 mRNA specific qRT-PCR was 86% while IHC 
showed a 92% concordance with ISH, and an 86% concordance with E6 mRNA by qRT-PCR 
suggesting that any of these duplex methods of detection is a reasonable approach [45].  
4. Conclusions  
Our ability to detect HPV infection in head and neck cancer samples has greatly outpaced our 
ability to use this information to alter therapy. However, ongoing clinical trials and improved 
understanding of the molecular mechanisms underlying HPV-associated cancers promise to enable 
personalization of therapy on the basis of HPV-infection. At the current time limitations of alternative 
methods for detection of HPV result in the use of IHC for p16 as the de facto test for HPV-positivity 
(Table 1). However, as throughput increases and costs decrease, it appears likely that technologies that 
can accurately identify a particular HPV-subtype will gain traction. 
Table 1. Pros and cons for tests of HPV status. 
Test Pros  Cons 
Southern blot  specific  sensitivity, requires large amounts of DNA, time intensive 
ISH  specific, performed on FFPE specimens  poor sensitivity 
PCR specific,  rapid  false  positives 
RT-PCR  sensitive and specific, rapid  requires intact RNA 
NGS 




perform in clinical labs,  
correlates with response 
not specific for HPV 
serology  easy to perform  No direct relationship to viral-associated cancer 
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